Stada Launches Lecigon In Germany And Austria
Value-Added Parkinson's Disease Treatment Rolled Out In Continental Europe
Stada is kicking off the launch of its Lecigon gel in continental Europe by rolling out the value-added product – which combines levodopa, carbidopa and entacapone infused via a lightweight pump – in Germany and Austria.
You may also be interested in...
Stada's Britannia Pharmaceuticals has acquired Sweden's Lobsor and its Lecigon gel formulation which is already approved in the Nordics and combines levodopa, carbidopa and entacapone infused via a lightweight pump. Meanwhile, Stada has also formed an alliance with MediPharm Labs for medical cannabis.
Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.
Medicines for Europe has called for fresh efforts to bolster the value added medicines sector and “level the playing field” with the US and its 505(b)(2) pathway, launching a new report setting out the three key areas in which greater EU action is needed.